Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daraxonrasib - REVOLUTION Medicines

Next Previous
Drug Profile

Daraxonrasib - REVOLUTION Medicines

Alternative Names: RAS(ON) inhibitor- REVOLUTION Medicines; Ras-IN-2; RASMULTI(ON) Inhibitor - REVOLUTION Medicines; RASONQUE; RMC-0706236; RMC-6236

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVOLUTION Medicines
  • Developer Bristol-Myers Squibb; Kura Oncology; REVOLUTION Medicines
  • Class Amides; Antineoplastics; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Indoles; Ketones; Methyl ethers; Piperazines; Pyridazines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Ras Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adenocarcinoma
  • Phase III Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I/II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 31 Aug 2026 Updated adverse events data from the phase-III RASolute 302 trial in Adenocarcinoma released by REVOLUTION Medicines
  • 27 Aug 2026 Phase-III clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, First-line therapy) in Australia, Brazil, Taiwan, United Kingdom (PO) (NCT07491445)
  • 27 Aug 2026 Phase-III clinical trials in Adenocarcinoma (Monotherapy, Metastatic disease, First-line therapy) in Australia, Brazil, Taiwan, United Kingdom (PO) (NCT07491445)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top